SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

May 01, 2013 12:54 ET

Implant Sciences Further Expands Technical Team With Ph.D. Physical Chemist

Industry Veteran Brings Experience in Gas Chromatography, Mass Spectroscopy, and Differential Ion Mobility to the Company

WILMINGTON, MA--(Marketwired - May 1, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that Dr. Quan Shi has joined the Company as Senior Analytical Chemist, reporting to Dr. Hacene Boudries, Director of Technology.

Dr. Shi is a senior scientist with a proven track record in system design from conception to manufacturing in the analytical instrumentation field. He brings in-depth experience in explosives, drugs and other trace chemical detection, gas chromatography, differential ion mobility spectrometry, and mass spectrometry to Implant Sciences. He was most recently Lead R&D Scientist at ThermoFisher Scientific, where he was responsible for new product development and governmental certification for explosives detectors. 

Previously, he held senior technical roles at Sionex Corporation where he was responsible for custom applications development around a differential ion mobility technology and worked closely with both commercial and governmental customers. As a Senior Research Scientist at Aerodyne Research, Dr. Shi was co-investigator for many projects funded by the Department of Defense (DoD), NASA, EPA and the National Institute of Standards and Technology (NIST). Dr. Shi earned his Ph.D. in Physical Chemistry from Boston College. He is widely published in peer-reviewed journals on subjects including explosives and drugs trace detection using ion mobility spectrometry.

"Dr. Shi brings tremendous expertise in a wide variety of methods for detecting trace amounts of explosives and drugs to Implant Sciences. He is highly regarded in the scientific community and has extensive experience in bringing products from R&D prototype to commercialization," stated Dr. Bill McGann, Implant Sciences' Chief Operating Officer. "We welcome Quan to the team, and look forward to his contributions in expanding the capabilities of our product line."

Implant Sciences' Vice President of Technology, Todd Silvestri added, "Dr. Shi has first-hand experience in getting trace detection products certified by regulatory agencies. We anticipate he will make a direct impact on our approval efforts worldwide."

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    Email Contact


    Investor Contact:
    Laurel Moody
    Email Contact